

November 15, 2019

To,
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Copy of Advertisement Published in Newspaper

Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed copies of advertisement published in Business Standard newspaper providing snapshot of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2019.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited


Krunal Shah
Company Secretary and Compliance Officer
Encl: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area, Thane(W), Mumbai - 400604, India

Tel: +91 22 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Sequent
Proven Ability In Life Sciences

India's Largest Animal Health Company



ALIVIRA



World's largest animal health injectable filed in EU



18 APIs filed in last 3 years in US



Turkey back on track; grew 63% over H1 FY20



Unaudited Financial results for the period ended September 30, 2019

Values in ₹ Mn	H1FY20	H1FY19	Growth%
Revenues	5,622	4,869	15.5%
EBITDA	763	570	34.0%
EBITDA margin%	13.6%	11.7%	190bps
PAT	398	200	2.0 x
PAT margin %	7.1%	4.1%	300bps

Note: Detailed financial results are available on stock exchange websites and company website